imatinib mesylate has been researched along with B-Cell Lymphoma in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Cheng, C; Lee, J; Liao, AT; Lin, C; Liu, B; Liu, C; Liu, I; Tomiyasu, H | 1 |
| Cao, CL; Cong, CL; Kang, SP; Kang, SR; Niu, HJ | 1 |
| Baybay, H; Berrady, R; Bono, W; El Hatimi, A; Gallouj, S; Khammar, Z; Lahlou, M; Lamchachti, L; Mernissi, FZ | 1 |
| Kim, JA | 1 |
| Chand, M; Keung, YK; Thakuri, M | 1 |
| Bordier, V; Decaudin, D; Dewulf, S; Di Santo, JP; Ekue, R; Grandjean, I; Lantz, O; Mathiot, C; Némati, F; Poupon, MF | 1 |
| Gupta, S; Janz, S; Lee, JS; Mushinski, JF; Owens, JD; Park, ES; Potter, M; Shaughnessy, JD; Wang, H; Woo, HG; Zhan, F | 1 |
| Countouriotis, A; Moore, TB; Sakamoto, KM | 1 |
3 review(s) available for imatinib mesylate and B-Cell Lymphoma
| Article | Year |
|---|---|
Targeted therapies for the treatment of cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Breast Neoplasms; Female; Humans; Imatinib Mesylate; Lymphoma, B-Cell; Male; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Trastuzumab | 2003 |
Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia.
Topics: Animals; Benzamides; Cell Line, Tumor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, abl; Genes, myc; Humans; Imatinib Mesylate; Lymphoma, B-Cell; Mice; Mice, Inbred BALB C; Models, Biological; Multiple Myeloma; Neoplasms, Plasma Cell; Piperazines; Pyrimidines; Signal Transduction; STAT Transcription Factors | 2007 |
Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Surface; Antineoplastic Agents; Benzamides; Hematologic Diseases; Humans; Imatinib Mesylate; Leukemia; Leukocyte Common Antigens; Lymphoma, B-Cell; Piperazines; Pyrimidines; Rituximab; Sialic Acid Binding Ig-like Lectin 3 | 2002 |
5 other study(ies) available for imatinib mesylate and B-Cell Lymphoma
| Article | Year |
|---|---|
Imatinib enhances the anti-tumour effect of doxorubicin in canine B-cell lymphoma cell line.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Imatinib Mesylate; Lymphoma, B-Cell; Protein Kinase Inhibitors | 2019 |
miRNA-21 sensitizes gastrointestinal stromal tumors (GISTs) cells to Imatinib via targeting B-cell lymphoma 2 (Bcl-2).
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Lymphoma, B-Cell; MicroRNAs; Piperazines; Pyrimidines | 2016 |
[Acquired ichthyosis and haematological malignancies: five cases].
Topics: Adult; Aged; Allopurinol; Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Cyclophosphamide; Doxorubicin; Etoposide; Female; Hematologic Neoplasms; Hodgkin Disease; Humans; Ichthyosis; Imatinib Mesylate; Leukemia, Myeloid, Accelerated Phase; Lung Neoplasms; Lymphoma, B-Cell; Male; Middle Aged; Paraneoplastic Syndromes; Parotid Neoplasms; Piperazines; Platelet Aggregation Inhibitors; Prednisone; Procarbazine; Pyrimidines; Retrospective Studies; Rituximab; Schizophrenia; Stomach Neoplasms; Vincristine | 2012 |
Imatinib mesylate associated with delayed hematopoietic recovery after concomitant chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Hematopoiesis; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Neoplasms, Second Primary; Piperazines; Pyrimidines | 2004 |
Imatinib mesylate reduces rituximab-induced tumor-growth inhibition in vivo on Epstein-Barr virus-associated human B-cell lymphoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Interactions; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Imatinib Mesylate; Lymphoma, B-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Piperazines; Pyrimidines; Rituximab; Xenograft Model Antitumor Assays | 2007 |